U.S. markets closed

Inspyr Therapeutics, Inc. (NSPX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0099-0.0000 (-0.50%)
At close: 3:57PM EDT

Inspyr Therapeutics, Inc.

2629 Townsgate Road
Suite 215
Westlake Village, CA 91360
United States
818 597 7552

Full Time Employees1

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael CainInterim CEO, CFO, Pres & Exec. DirectorN/AN/A1983
Dr. John T. IsaacsCo-Founder, Chairman of Scientific Advisory Board & Chief Scientific AdvisorN/AN/AN/A
Dr. Samuel R. DenmeadeCo-Founder, Chief Clinical Advisor and Member of Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Inspyr Therapeutics, Inc., a pharmaceutical company, focuses on the research and development of therapeutics for the treatment of cancer. Its immune-oncology lead asset is RT-AR001, an adenosine A2B receptor antagonist for tumor infiltration. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was incorporated in 2003 and is based in Westlake Village, California.

Corporate Governance

Inspyr Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.